Sanofi Stock: Will This Be a Big Pharma Winner in 2014?

Shares of Sanofi (NYSE: SNY  ) trailed the broader market last year as the company suffered an FDA rejection of its multiple sclerosis drug Lemtrada, and saw revenue fall due to patent expirations. However, CEO Chris Viehbacher recently stated in a recent CNBC interview that the company's pipeline is one of the top five in the big pharma industry.

Is he right, or overly optimistic?

Motley Fool analyst Max Macaluso examines this statement and Sanofi's overall business in the following video. He focuses on the key factors that could see the company return to growth this year, and Sanofi's unique strategy to avoid another patent cliff.

Biotech stocks are known for volatility. What's the best way to play this space?
The best way to play the biotech space is to find companies that shun the status quo and, instead, discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report, "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2815216, ~/Articles/ArticleHandler.aspx, 9/5/2015 2:11:20 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Max Macaluso

Max is the Technology, Biopharma & Health Care Bureau Chief at Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.

Today's Market

updated 4 hours ago Sponsored by:
DOW 16,102.38 -272.38 -1.66%
S&P 500 1,921.22 -29.91 -1.53%
NASD 4,683.92 -49.58 -1.05%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/4/2015 4:00 PM
SNY $48.45 Down -1.12 -2.26%
Sanofi (ADR) CAPS Rating: *****
ALNY $97.80 Up +0.55 +0.57%
Alnylam Pharmaceut… CAPS Rating: ***
NVO $54.31 Down -0.85 -1.54%
Novo Nordisk CAPS Rating: *****
REGN $499.99 Down -8.52 -1.68%
Regeneron Pharmace… CAPS Rating: ***